Human Molecular Genetics Advance Access published online on October 15, 2004
Human Molecular Genetics, doi:10.1093/hmg/ddh323
© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP and Collège de France, B.P.10142, 67404 Illkirch Cedex, C.U. de Strasbourg, France
* To whom correspondence should be addressed. E-mail: apujol{at}igbmc.u-strasbg.fr.
X-linked adrenoleukodystrophy (X-ALD) is a severe neurodegenerative disease caused by loss of function of the peroxisomal transporter ABCD1 (ALD), which results in accumulation of very-long-chain fatty acids (VLCFAs) in organs and serum, central demyelination and peripheral axonopathy, and Addison's disease. Knockout of the ALD gene in the mouse (ALD-) results in an adrenomyeloneuropathy-like disease (AMN, a late onset form of X-ALD). In the present study, we demonstrate that axonal damage occurs as first pathological event in this model, followed by myelin degeneration. We show that this phenotype can be modulated through expression levels of an ALD-related gene (ALDR/ABCD2), its closest paralog and a target of PPAR
Article
Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy
2 Institut de Neuropatologia, Hospital Universitari de Bellvitge, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
3 Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP and Collège de France, B.P.10142, 67404 Illkirch Cedex, C.U. de Strasbourg, France; Institut de Bioquimica Clinica, c/ Mejia Lequerica, s/n 08028 Barcelona, Spain
4 Societé Neurofit, SA 67404 Illkirch Cedex, C. U. de Strasbourg, France
5 Institut de Bioquimica Clinica, c/ Mejia Lequerica, s/n 08028 Barcelona, Spain
Abstract 
and SREBP transcription factors. Overexpression of ALDR in ALD- mice prevents both VLCFAs accumulation and the neurodegenerative features, whereas double mutants for ALD and ALDR exhibit an earlier onset and more severe disease (including signs of inflammatory reaction) when compared to ALD single mutants. Thus, our results provide direct evidence for functional redundancy/overlap between both transporters in vivo and highlight ALDR as therapeutic target for treatment of X-ALD.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Singh, A. K. Singh, and M. A. Contreras Peroxisomal Dysfunction in Inflammatory Childhood White Matter Disorders: An Unexpected Contributor to Neuropathology J Child Neurol, September 1, 2009; 24(9): 1147 - 1157. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Singh, M. Khan, and I. Singh Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy J. Lipid Res., January 1, 2009; 50(1): 135 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fourcade, M. Ruiz, C. Camps, A. Schluter, S. M. Houten, P. A. W. Mooyer, T. Pampols, G. Dacremont, R. J. A. Wanders, M. Giros, et al. A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E211 - E221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fourcade, J. Lopez-Erauskin, J. Galino, C. Duval, A. Naudi, M. Jove, S. Kemp, F. Villarroya, I. Ferrer, R. Pamplona, et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy Hum. Mol. Genet., June 15, 2008; 17(12): 1762 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Brolinson, S. Fourcade, A. Jakobsson, A. Pujol, and A. Jacobsson Steroid Hormones Control Circadian Elovl3 Expression in Mouse Liver Endocrinology, June 1, 2008; 149(6): 3158 - 3166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biserni, F. Giannessi, A. F. Sciarroni, F. M. Milazzo, A. Maggi, and P. Ciana In Vivo Imaging Reveals Selective Peroxisome Proliferator Activated Receptor Modulator Activity of the Synthetic Ligand 3-(1-(4-Chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886) Mol. Pharmacol., May 1, 2008; 73(5): 1434 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hulshagen, O. Krysko, A. Bottelbergs, S. Huyghe, R. Klein, P. P. Van Veldhoven, P. P. De Deyn, R. D'Hooge, D. Hartmann, and M. Baes Absence of Functional Peroxisomes from Mouse CNS Causes Dysmyelination and Axon Degeneration J. Neurosci., April 9, 2008; 28(15): 4015 - 4027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Weinhofer, M. Kunze, H. Rampler, A. L. Bookout, S. Forss-Petter, and J. Berger Liver X Receptor {alpha} Interferes with SREBP1c-mediated Abcd2 Expression: NOVEL CROSS-TALK IN GENE REGULATION J. Biol. Chem., December 16, 2005; 280(50): 41243 - 41251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ferrer, J. P. Kapfhammer, C. Hindelang, S. Kemp, N. Troffer-Charlier, V. Broccoli, N. Callyzot, P. Mooyer, J. Selhorst, P. Vreken, et al. Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage Hum. Mol. Genet., December 1, 2005; 14(23): 3565 - 3577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Asheuer, I. Bieche, I. Laurendeau, A. Moser, B. Hainque, M. Vidaud, and P. Aubourg Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy Hum. Mol. Genet., May 15, 2005; 14(10): 1293 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gondcaille, M. Depreter, S. Fourcade, M. R. Lecca, S. Leclercq, P. G.P. Martin, T. Pineau, F. Cadepond, M. ElEtr, N. Bertrand, et al. Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator J. Cell Biol., April 11, 2005; 169(1): 93 - 104. [Abstract] [Full Text] [PDF]
|
|